CNBC's Morgan Brennan reports on the FDA approving Portola's blood-thinning drug and the company's stock reaction. » Read More
Michael Golway, president and CEO at Advanced Solutions explains how his team of engineers are working toward the goal of 3D printing human organs. » Read More
Hedge fund billionaire John Paulson has joined the board of Valeant Pharmaceuticals.
Merck is our number pick, says Tony Butler, Guggenheim Securities, providing his top plays in the pharma space.
CNBC's Meg Tirrell reports biotech companies are watching what will be included in President Trump's executive order on drug pricing, and the industry is optimistic about new products in the pipeline.
Roche-backed Foundation Medicine will bring its genomic sequencing of tumors to China in the third quarter.
CNBC's Meg Tirrell reports from the Heartland Health Summit about President Trump's executive order on lower drug prices and what pharma CEOs have been saying.
Ricks advocated for faster FDA approval on generic drugs and "innovative breakthroughs."
Allergan CEO Brent Saunders has some ideas about what may be in an executive order, and believes it could be good for industry and patients.
Drug stocks fell on the back of a report that President Donald Trump was ready to issue an executive order aimed at lowering drug prices.
The full interview with Allergan CEO Brent Saunders.
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
Mylan's decision to "gouge" consumers on lifesaving EpiPen devices is corporate "greed on steroids," consumer advocate Ralph Nader tells CNBC.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Ralph Nader, former presidential candidate and consumer advocate, responds to Mylan and what she had to say about the EpiPen pricing outrage.
CNBC's Jim Cramer fires back Thursday on comments from Mylan about pricing of the auto-injection device EpiPen.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Shares of Mylan held slightly lower in afternoon trade, giving up earlier gains of more than 4 percent.
Mylan announced plans to boost access to its EpiPen Auto-Injector by expanding programs for patients who are facing higher out-of-pocket costs.
Mylan CEO Heather Bresch speaks to CNBC on Thursday about the controversy surrounding her company's 400-percent price hike to EpiPens over the past few years.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one's more frustrated than her.
Get the best of CNBC in your inbox